Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Increase in Short Interest

Key Points

• Tiziana Life Sciences Ltd experienced a significant increase in short interest by 20.5% in August, bringing the total to 791,900 shares.
• The company's stock traded up to $1.78, with a short-interest ratio of 2.3 days, suggesting a moderate level of short selling activity.
• Institutional investors have shown increased interest in Tiziana, with notable purchases including a new position from Dauntless Investment Group valued at approximately $1.88 million.

Tiziana Life Sciences Ltd (NASDAQ:TLSA - ) was the recipient of a significant increase in short interest in August. As of August 31st, there was short interest totaling 791,900 shares, an increase of 20.5% from the August 15th total of 657,200 shares. Approximately 1.3% of the company's shares are sold short. Based on an average daily trading volume, of 345,800 shares, the short-interest ratio is presently 2.3 days. Based on an average daily trading volume, of 345,800 shares, the short-interest ratio is presently 2.3 days. Approximately 1.3% of the company's shares are sold short.

Tiziana Life Sciences Stock Performance

Shares of TLSA traded up $0.12 during midday trading on Thursday, hitting $1.78. 466,023 shares of the stock traded hands, compared to its average volume of 578,424. The business's 50 day moving average price is $1.87 and its two-hundred day moving average price is $1.52. Tiziana Life Sciences has a 1-year low of $0.63 and a 1-year high of $2.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Dauntless Investment Group LLC bought a new position in shares of Tiziana Life Sciences during the 1st quarter valued at about $1,879,000. OMERS ADMINISTRATION Corp bought a new position in shares of Tiziana Life Sciences in the first quarter valued at approximately $156,000. Bison Wealth LLC bought a new stake in Tiziana Life Sciences during the fourth quarter worth $30,000. Jane Street Group LLC grew its position in shares of Tiziana Life Sciences by 968.2% in the first quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock valued at $181,000 after purchasing an additional 151,858 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Tiziana Life Sciences during the second quarter worth about $39,000.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.